Cargando…

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment. This first-in-human phase 1/1b study included sitravatinib d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauer, Todd, Cho, Byong Chul, Heist, Rebecca, Bazhenova, Lyudmila, Werner, Theresa, Goel, Sanjay, Kim, Dong-Wan, Adkins, Douglas, Carvajal, Richard D., Alva, Ajjai, Eaton, Keith, Wang, Judy, Liu, Yong, Yan, Xiaohong, Christensen, Jamie, Neuteboom, Saskia, Chao, Richard, Pant, Shubham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395446/ https://www.ncbi.nlm.nih.gov/pubmed/35767205 http://dx.doi.org/10.1007/s10637-022-01274-y

Ejemplares similares

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor
por: Yang, Yuqi, et al.
Publicado: (2020)

Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
por: Oliva, Marc, et al.
Publicado: (2021)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
por: Zhang, Yvyin, et al.
Publicado: (2023)

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
por: Karam, Jose A., et al.
Publicado: (2023)

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
por: Zhao, Jun, et al.
Publicado: (2023)

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro
por: Yang, Yuqi, et al.
Publicado: (2020)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini, Nicholas, et al.
Publicado: (2021)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
por: Patwardhan, Parag P., et al.
Publicado: (2015)

Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma
por: Nguyen, Charles B., et al.
Publicado: (2022)

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2022)

Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia
por: Alva, Ajjai, et al.
Publicado: (2015)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Ipilimumab induced digital vasculitis
por: Padda, Amrita, et al.
Publicado: (2018)

Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on Clinical, Radiomics, and Deep-Learning Descriptors
por: Sun, Di, et al.
Publicado: (2023)

Epigenetics in Prostate Cancer
por: Albany, Costantine, et al.
Publicado: (2011)

A Stochastic Markov Chain Model to Describe Lung Cancer Growth and Metastasis
por: Newton, Paul K., et al.
Publicado: (2012)

A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer
por: Cohen, Roger B, et al.
Publicado: (2014)

Bladder Cancer Treatment Response Assessment in CT using Radiomics with Deep-Learning
por: Cha, Kenny H., et al.
Publicado: (2017)

Bladder Cancer Segmentation in CT for Treatment Response Assessment: Application of Deep-Learning Convolution Neural Network—A Pilot Study
por: Cha, Kenny H., et al.
Publicado: (2016)

A Retrospective Review of the Frequency and Nature of Acute Hypersensitivity Reactions at a Medium-Sized Infusion Center: Comparison to Reported Values and Inconsistencies Found in Literature
por: DeMoor, Patricia A., et al.
Publicado: (2011)

Entropy, complexity, and Markov diagrams for random walk cancer models
por: Newton, Paul K., et al.
Publicado: (2014)

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy
por: Yu, Li, et al.
Publicado: (2022)

Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer
por: Shishido, Stephanie N., et al.
Publicado: (2019)

A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies
por: Taylor, Matthew H., et al.
Publicado: (2020)

Understanding the Variability of Certain Biological Properties of H1N1pdm09 Influenza Viruses
por: Al Farroukh, Mohammad, et al.
Publicado: (2022)

Detection of CTC Clusters and a Dedifferentiated RNA‐Expression Survival Signature in Prostate Cancer
por: Kozminsky, Molly, et al.
Publicado: (2018)

Deep Learning Approach for Assessment of Bladder Cancer Treatment Response
por: Wu, Eric, et al.
Publicado: (2019)

Effect of Central Administration of Brain-Derived Neurotrophic Factor (BDNF) on Behavior and Brain Monoamine Metabolism in New Recombinant Mouse Lines Differing by 5-HT(1A) Receptor Functionality
por: Bazovkina, Darya, et al.
Publicado: (2021)

Non-Mouse-Adapted H1N1pdm09 Virus as a Model for Influenza Research
por: Kiseleva, Irina, et al.
Publicado: (2020)

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
por: Tsigelny, Igor F., et al.
Publicado: (2015)

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
por: Bazhenova, Lyudmila, et al.
Publicado: (2021)

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Wang, Michelle, et al.
Publicado: (2023)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
por: Kato, Shumei, et al.
Publicado: (2015)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
por: Grivas, Petros, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_etc936qjv7k394u1ijj279913r